Heidelberg Pharma AG (HPHA) Stock Statistics & Valuation Metrics

Heidelberg Pharma AG has a market cap or net worth of €131.46M. The enterprise value is €117.65M.

Heidelberg Pharma AG has 46,784,317 shares outstanding. The number of shares has decreased by -2.65% in one year.

Heidelberg Pharma AG’s return on equity (ROE) is 3.87 and return on invested capital (ROIC) is -175.53%.

The current PE Ratio of Heidelberg Pharma AG is ―. Heidelberg Pharma AG’s PEG ratio is -0.03.

In the last 12 months, Heidelberg Pharma AG had revenue of 1.46M and earned -42.28M in profits. Earnings per share was -0.91.

In the last 12 months, operating cash flow was -31.60M and capital expenditures -128.65K, giving a free cash flow of -31.70M billion.

Heidelberg Pharma AG pays an annual dividend of ―, resulting in a dividend yield of ―

Heidelberg Pharma AG upcoming earnings date is Jul 15, 2026, Before Open (Confirmed).

Heidelberg Pharma AG as a current ratio of 2.53, with Debt / Equity ratio of -10.67%

In the past 12 months, Heidelberg Pharma AG has paid 1.05M in taxes.

Heidelberg Pharma AG EV to EBITDA ratio is -2.70, with an EV/FCF ratio of -3.80.

Heidelberg Pharma AG has €14.98M in cash and marketable securities with €1.16M in debt, giving a net cash position of €13.81M billion.

Gross margin is -82.82%, with operating margin of -3255.36%, and net profit margin of -2901.15%.

The average price target for Heidelberg Pharma AG is ―, which is 11.43% higher than the current price. The consensus rating is ―